Avastin, the blockbuster drug that just lost approval for treating breast cancer, now looks disappointing against ovarian cancer, too. Two studies found it did not improve survival for most of these patients and kept their disease from worsening for only a few months, with more side effects.
The Genentech drug won approval in Europe last week for advanced ovarian cancer. But its South San Francisco-based maker has no immediate plans to seek the same approval in the United States. After talking with the Food and Drug Administration, "we do not believe the data will support approval," although no final decision has been made, said Charlotte Arnold, a spokeswoman for Genentech, part of the Swiss company Roche.
Results of the studies are in Thursday's New England Journal of Medicine.
Thursday, December 29, 2011
Another blow for Genentech as Avastin fails in tests on ovarian cancer - San Jose Mercury News